Drug intelligence / Profile preview

Algidol Zen

Development stage
Unknown
Lead developer
Gelpharma
Modality
Small Molecules
Administration
Oral
01

Overview

Algidol Zen is a combination pharmaceutical product developed by Gelpharma, containing ibuprofen (200 mg) and diphenhydramine (25 mg). Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins to provide analgesic and anti-inflammatory effects. Diphenhydramine is a first-generation antihistamine that functions as an antagonist at the histamine H1 receptor; it crosses the blood-brain barrier to produce sedative effects, serving as a sleep aid. The product is formulated as a soft gelatin capsule for oral administration, specifically targeting nighttime relief of mild to moderate pain and associated insomnia. It is currently approved and marketed in Mexico.

Brand names
Algidol Zen
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Algidol Zen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algidol Zen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call